Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 5,126 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: HIV Infection
Interventions: Bruthas Project, Standard HIV Testing and Counseling; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 396 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: X-linked Hypophosphatemia
Interventions: burosumab, Placebo; Biological · Other
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more

Conditions: SARS-CoV-2, COVID-19
Interventions: Hydroxychloroquine, Azithromycin, Placebo oral tablet; Drug
Lead sponsor: Salomeh Keyhani MD; Federal
Eligibility: 216 Months and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Crohn Disease
Interventions: Etrolizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 62
States / cities: Arcadia, California • La Jolla, California • Long Beach, California + 53 more

Conditions: End Stage Liver Disease, Sarcopenia, Liver Cirrhoses
Interventions: Exercise Program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Durham, North Carolina

Conditions: Psychedelic Experiences, Neuroimaging, Healthy Volunteers
Interventions: Psilocybin; Drug
Lead sponsor: Robin Carhart-Harris, PhD, MA; Other
Eligibility: 21 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain Injury
Interventions: Neural Pathfinder Training, Brain Health Education; Behavioral
Lead sponsor: VA Northern California Health Care System; Federal
Eligibility: 24 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Martinez, California • San Francisco, California

Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions: PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure
Interventions: ShortCut™; Device
Lead sponsor: Pi-cardia; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Avelumab, Talazoparib, Talazoparib Tosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 325
States / cities: Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more

Conditions: Substance Abuse, HIV Infections
Interventions: Bupropion, Placebo; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer, Advanced Prostate Carcinoma
Interventions: Hyperpolarized C13, Magnetic Resonance Imaging (MRI); Drug · Procedure
Lead sponsor: Ivan de Kouchkovsky, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Staphylococcal Infection
Interventions: Trimethoprim-sulfamethoxazole, Placebo, Clindamycin; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 85 Years
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions: ABBV-RGX-314, Ranibizumab (LUCENTIS®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 89
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more

Conditions: HIV Infections
Interventions: Thymic Humoral Factor, Zidovudine; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Lung Cancer Metastatic, EGFR Gene Mutation
Interventions: Osimertinib, Alisertib; Drug
Lead sponsor: Collin Blakely; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Infertility, Female
Interventions: Caloric Restriction, Orlistat, Moderate physical activity; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: San Francisco, California • Augusta, Georgia • Southfield, Michigan + 7 more

Conditions: Liver Disease
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 2,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 8
States / cities: La Jolla, California • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: Lung Transplantation
Interventions: OCS Lung Preservation; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Heart Failure
Interventions: HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 50 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more

Conditions: Solid Tumors
Interventions: RMC-5552; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Irvine, California • Sacramento, California • San Francisco, California + 5 more

Conditions: Stroke
Interventions: Sentinel® Cerebral Protection System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 41
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 37 more

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Interventions: Not listed
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 14 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 5 more

Conditions: Scleroderma, Systemic
Interventions: Nintedanib, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more

Search by objective public record fields.

A Randomized Controlled Trial of the Bruthas Project

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

Exercise Intervention in Liver Transplant Patients

Neural and Physiological Correlates of Psychedelic Sub-states

Remotely Deployed TBI Study

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

The ShortCut™ Study Protocol

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility

Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2

OCS Lung System EXPAND II Trial

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis